BIIB
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FBIIB.O%2Fkey-developments%2Farticle%2F2681240&ei=oIaaUqDjE4qw0AGZAw&usg=AFQjCNFSGBBflPmHfKXwthP7VyeEk5oLAQ
Biogen Idec Inc Issues FY 2013 Guidance; EPS Guidance Below Analysts' Estimates
Monday, 28 Jan 2013 06:30am EST
Biogen Idec Inc announced that for fiscal 2013, it expects revenue growth to be approximately 10%, non-GAAP diluted EPS to be between $7.15 and $7.25 and GAAP diluted EPS to be between $6.45 and $6.55. The Company reported revenues of $5.5 billion in fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $5.9 billion and EPS of $7.27 for fiscal 2013.Â 
